Glanzmann's disease
RecruitingStudy on the Safety and Effects of HMB-001 for Patients with Glanzmann Thrombasthenia
- Disease:Glanzmann's disease
- Substances:Hmb-001
Belgium- Participants:18–64 years
- Substances:Hmb-001
- Sponsor:Hemab ApS
Rare diseases
Investigational molecules
Locations
Nordre Fasanvej 215, 2000 Frederiksberg, Denmark
Hemab ApS focuses on Glanzmann thrombasthenia, a rare platelet function disorder associated with impaired clot formation and recurrent bleeding.
The sponsor’s research interest centres on clinical outcomes linked to bleeding control and the management of inherited disorders of haemostasis.
Hemab ApS runs clinical trials in conditions such as Glanzmann's disease, among others.
Clinical trials run by this sponsor – those enrolling participants first.
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.